Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 17.9% in November

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,450,000 shares, an increase of 17.9% from the November 15th total of 1,230,000 shares. Approximately 1.7% of the shares of the company are short sold. Based on an average daily trading volume, of 487,900 shares, the short-interest ratio is presently 3.0 days.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $5.00 to $4.00 in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a report on Monday, November 11th. Finally, LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Monday, September 16th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.75.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock remained flat at $1.46 on Monday. The stock had a trading volume of 173,642 shares, compared to its average volume of 438,574. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.34. The stock has a market cap of $200.88 million, a price-to-earnings ratio of -4.07 and a beta of 0.89. The business has a fifty day simple moving average of $1.68 and a two-hundred day simple moving average of $1.41.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. As a group, research analysts anticipate that Compass Therapeutics will post -0.35 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds have recently bought and sold shares of CMPX. Vanguard Group Inc. increased its holdings in shares of Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after purchasing an additional 71,008 shares during the period. Geode Capital Management LLC increased its stake in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after buying an additional 19,095 shares during the period. Bank of New York Mellon Corp lifted its position in Compass Therapeutics by 12.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock worth $284,000 after buying an additional 31,433 shares in the last quarter. Barclays PLC boosted its stake in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after buying an additional 112,614 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after acquiring an additional 70,200 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.